Brand name: Xeljanz
Xeljanz is a medicine containing the active ingredient(s) tofacitinib. On this page you will find out more about Xeljanz, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: tofacitinib
Information for medicine and pack size:
Xeljanz 5 mg film-coated tablet, 56
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
XELJANZ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to methotrexate. XELJANZ can be used alone or in combination with nonbiological DMARDs, including methotrexate. Therapy with XELJANZ should be initiated and monitored by a rheumatologist or specialist physician with expertise in the management of rheumatoid arthritis.
Table of characteristics
| Active ingredient | |
|---|---|
| Visual appearance |
White, round, film-coated tablet debossed with 'Pfizer' on one side and 'JKI 5' on the other side.
Images are the copyright of the Pharmacy Guild of Australia |
| Dosage Form | Tablet, film coated |
| Route of administration | Oral |
| Medicine schedule |
14 tablets: Prescription Only Medicine, or Prescription Animal Remedy
56 tablets: Prescription Only Medicine, or Prescription Animal Remedy
|
There is one type of pack available.
Pack type 1
| Type | Blister Pack |
|---|---|
| Storage temperature | Store below 30 degrees Celsius |
| Storage conditions | No information available |
| Life time | 3 Years |
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.
Need more information?
These trusted information partners have more on this topic.
Found 1 results
Xeljanz Tablets - myDr.com.au
Xeljanz Tablets - Consumer Medicines Information leaflets of prescription and over-the-counter medicines
Read more on myDr – Consumer Medicine Information website
Found 1 results
Janus kinase inhibitors: Mechanisms of action | Issue 5 | Volume 37 | Australian Prescriber
The Janus kinase family of enzymes are associated with cytokine receptors on the surface of
Read more on Australian Prescriber website
